Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:43:03.320Z.
Calculation as of: 2026-10-06T15:43:03.320Z.
Quote observation: 2026-10-06T15:40:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a3ccde1bd0df5c55ebc0148063105fff0bf751cb52a3071af3e3331f6001fbe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$509.10M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$490.16M
Price/OCF Ratio
11.91
TTM Avg
8.06
3Y Avg
6.53
5Y Avg
6.99
Market Cap
$514.53M
Price/OCF Ratio
375.57
TTM Avg
294.84
3Y Avg
294.84
5Y Avg
294.84
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $501.67M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $491.69M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $490.16M | 11.91 | 8.06 | 6.53 | 6.99 |
| 908 Devices Inc. (MASS)vs › | $514.53M | 375.57 | 294.84 | 294.84 | 294.84 |
| Arvinas, Inc. (ARVN)vs › | $482.94M | N/A | 5.46 | 5.49 | 10.64 |
| Altimmune, Inc. (ALT)vs › | $521.19M | N/A | 0.26 | 0.26 | 0.26 |
| Crescent Biopharma, Inc. (CBIO)vs › | $522.43M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.79M | N/A | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $479.89M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
